Core Viewpoint - Recently, Fosun Pharma announced a licensing agreement with UK biotech company Sitala Bio Ltd for the small molecule inhibitor FXS6837, granting Sitala global development, production, and commercialization rights outside of China and Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary will retain development, production, and commercialization rights for FXS6837 within China and the aforementioned regions [1] - Sitala will pay up to $190 million in non-refundable upfront payments and milestone payments related to development and commercialization [1] - Fosun Pharma will receive shares worth $5 million from Sitala at no cost [1] Group 2: Future Financial Implications - Based on annual net sales performance of the licensed product in the licensed territories, Sitala will pay up to $480 million in sales milestone payments to Fosun Pharma [1]